Drug Details

General Information of the Drug (ID: DR4093)
Name
Chlorambucil
Synonyms
chlorambucil; 305-03-3; Ambochlorin; Chloroambucil; Leukeran; Chloraminophen; Chlorbutin; Chloraminophene; Chlorobutine; Amboclorin; Chlorbutine; Chlorobutin; Linfolizin; Linfolysin; Ecloril; Elcoril; Phenylbutyric acid nitrogen mustard; Chlocambucil; Lympholysin; Leukersan; Leukoran; 4-{4-[bis(2-chloroethyl)amino]phenyl}butanoic acid; Cb l348; NSC-3088; CB 1348; Phenylbuttersaeure-lost; Benzenebutanoic acid, 4-[bis(2-chloroethyl)amino]-; NSC 3088; Rcra waste number U035; NCI-C03485; 4-[p-[Bis(2-chloroethyl)amino]phenyl]butyric acid; chlorambucilddv; 4-[4-[bis(2-chloroethyl)amino]phenyl]butanoic acid; N,N-Di-2-chloroethyl-gamma-p-aminophenylbutyric acid; 4-(Bis(2-chloroethyl)amino)benzenebutanoic acid; p-(N,N-Di-2-chloroethyl)aminophenyl butyric acid; 4-(p-Bis(beta-chloroethyl)aminophenyl)butyric acid; UNII-18D0SL7309; 4-(4-(Bis(2-chloroethyl)amino)phenyl)butanoic acid; CHEBI:28830; NSC3088; 4-[Bis(2-chloroethyl)amino]benzenebutyric acid; 4-[Bis(2-chloroethyl)amino]benzenebutanoic acid; CHEMBL515; gamma-[p-Di(2-chloroethyl)aminophenyl]butyric acid; Benzenebutanoic acid, 4-(bis(2-chloroethyl)amino)-; MLS000028443; Chloorambucol; Chlorbutinum; Elcorin; 4-(Bis(2-chloroethyl)amino)phenylbutyric acid; 4-(p-(Bis(2-chloroethyl)amino)phenyl)butyric acid; gamma-(p-Di(2-chloroethyl)aminophenyl)butyric acid; Butyric acid, 4-(p-bis(2-chloroethyl)aminophenyl)-; MFCD00021783; 18D0SL7309; Kyselina 4-(N,N-bis-(2-chlorethyl)-p-aminofenyl)maselna; NCGC00015199-08; Chlorambucilum; Clorambucile; Clorambucilo; CAS-305-03-3; SMR000058372; Clorambucile [DCIT]; DSSTox_CID_263; Leukeran tablets; 4-[Bis(2-chloroethyl)amino]phenylbutyric acid; DSSTox_RID_75472; DSSTox_GSID_20263; 4-(4-[Bis(2-chloroethyl)amino]phenyl)butyric acid; .gamma.-[p-Di(2-chloroethyl)aminophenyl]butyric acid; Butyric acid, 4-[p-[bis(2-chloroethyl)amino]phenyl]-; Chlorambucilum [INN-Latin]; Clorambucilo [INN-Spanish]; p-N,N-Di-(.beta.-chloroethyl)aminophenyl butyric acid; N,N-Di-2-chloroethyl-.gamma.-p-aminophenylbutyric acid; CB-1348; CCRIS 126; Phenylbuttersaeure-lost [German]; HSDB 3026; SR-01000000062; LEUKERAN (TN); 4-[4-[Bis(2-chloroethyl)amino]phenyl]butyric Acid; EINECS 206-162-0; .gamma.-(p-bis(2-chloroethyl)aminophenyl)butyric acid; .gamma.-[p-bis(2-chloroethyl)aminophenyl]butyric acid; 4-(p-Bis(.beta.-chloroethyl)aminophenyl)butyric acid; 4-[p-Bis(.beta.-chloroethyl)aminophenyl]butyric acid; RCRA waste no. U035; Butyric acid, 4-(p-[bis(2-chloroethyl)amino]phenyl)-; BRN 0999011; Chlorambucil [USP:INN:BAN]; AI3-26083; p-(N,N-Di-2-chlorethylaminophenyl)butyric acid; para-(Di(2-chloroethyl)aminophenyl)butyric acid; Chlorambucil,(S); gamma-(p-bis(2-chloroethyl)aminophenyl)butyricacid; Butanoic acid, 4-(bis(2-chloroethyl)amino) benzene; gamma-(p-Bis(2-chloroethyl)aminophenyl)butyric acid; phenyl)butanoic acid; p-N,N-Di-(beta-chloroethyl)aminophenyl butyric acid; Butyric acid, 4-(p-(bis(2-chloroethyl)amino)phenyl); para-N,N-Di(beta-chloroethyl)aminophenyl butyric acid; N,N-Di-2-chloroethyl-gamma-para-aminophenyl butyric acid; Opera_ID_51; PubChem21331; Spectrum_000118; Kyselina 4-(N,N-bis-(2-chlorethyl)-p-aminofenyl)maselna [Czech]; Prestwick0_001079; Prestwick1_001079; Prestwick2_001079; Prestwick3_001079; Spectrum2_000065; Spectrum3_000336; Spectrum4_000273; Spectrum5_000677; Lopac-C-0253; Epitope ID:139977; SCHEMBL4308; Lopac0_000227; WLN: QV3R DN2G2G; BSPBio_001098; BSPBio_001971; KBioGR_000766; KBioSS_000558; 4-14-00-01715 (Beilstein Handbook Reference); MLS001076130; DivK1c_000688; SPECTRUM1500171; Chlorambucil (JAN/USP/INN); SPBio_000249; SPBio_002999; BPBio1_001208; GTPL7143; ZINC1115; DTXSID7020263; HMS502C10; KBio1_000688; KBio2_000558; KBio2_003126; KBio2_005694; KBio3_001191; NINDS_000688; HMS1571G20; HMS1920M15; HMS2090M19; HMS2091A22; HMS2098G20; HMS2235A04; HMS3259I10; HMS3372O04; HMS3652P08; Pharmakon1600-01500171; 4-(4-(bis(2-chloroethyl)amino); AMY33445; BCP28394; NCI-3088; Tox21_110096; Tox21_201390; Tox21_302996; BDBM50003677; CCG-39872; NSC756674; s4288; AKOS024319346; Tox21_110096_1; Chlorambucil, purum, >=98.0% (T); CS-3118; DB00291; GS-6200; LP00227; MCULE-2575006904; NC00555; NSC-756674; SDCCGSBI-0050215.P005; IDI1_000688; NCGC00015199-01; NCGC00015199-02; NCGC00015199-03; NCGC00015199-04; NCGC00015199-05; NCGC00015199-06; NCGC00015199-07; NCGC00015199-09; NCGC00015199-10; NCGC00015199-11; NCGC00015199-12; NCGC00015199-13; NCGC00015199-14; NCGC00015199-15; NCGC00015199-16; NCGC00015199-17; NCGC00015199-19; NCGC00015199-20; NCGC00023250-00; NCGC00023250-03; NCGC00023250-04; NCGC00023250-05; NCGC00023250-06; NCGC00023250-07; NCGC00023250-08; NCGC00023250-09; NCGC00023250-10; NCGC00256464-01; NCGC00258941-01; AK327627; BP-24028; HY-13593; NCI60_002639; SBI-0050215.P004; AB0093202; DB-047794; AB00051938; EU-0100227; FT-0617365; ST50410766; SW197258-4; A14252; A18607; C 0253; C06900; D00266; AB00051938-14; AB00051938-15; AB00051938_16; 305C033; Q415939; 4[p-Bis(.beta.-chloroethyl)aminophenyl]butyric acid; Butanoic acid, 4-(bis(2-chloroethyl)amino)benzene-; SR-01000000062-2; SR-01000000062-4; SR-01000000062-7; W-106940; .gamma.-(p-bis(2-chloroethyl)aminophenyl)butyricacid; BRD-K29458283-001-04-2; BRD-K29458283-001-05-9; BRD-K29458283-001-17-4; 4-(4-[Bis(2-chloroethyl)amino]phenyl)butanoic acid #; Z1558572529; 4-[4-(N,N-bis(2-chloroethyl)-amino]phenyl)butanoic acid; Chlorambucil, European Pharmacopoeia (EP) Reference Standard; Chlorambucil, United States Pharmacopeia (USP) Reference Standard; Chlorambucil for system suitability, European Pharmacopoeia (EP) Reference Standard
    Click to Show/Hide
Molecular Type
Small molecule
Disease Chronic lymphocytic leukaemia [ICD-11: 2A82] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C14H19Cl2NO2
PubChem CID
2708
Canonical SMILES
C1=CC(=CC=C1CCCC(=O)O)N(CCCl)CCCl
InChI
1S/C14H19Cl2NO2/c15-8-10-17(11-9-16)13-6-4-12(5-7-13)2-1-3-14(18)19/h4-7H,1-3,8-11H2,(H,18,19)
InChIKey
JCKYGMPEJWAADB-UHFFFAOYSA-N
CAS Number
CAS 305-03-3
ChEBI ID
CHEBI:28830
TTD Drug ID
D0V8QT
DrugBank ID
DB00291
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Vinblastine      Catharanthus roseus     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Experimental
                    Result(s)		 The treatment of advanced and recurrent Hodgkin's disease with chlorambucil, vinblastine, procarbazine and prednisone in combination.
Target and Pathway
Target(s) DNA replication (DNA repli)  Molecule Info  [3]
References
Reference 1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7143).
Reference 2 The treatment of advanced and recurrent Hodgkin's disease with chlorambucil, vinblastine, procarbazine and prednisone in combination. Cancer Treat Rev. 1979 Jun;6 Suppl:107-13.
Reference 3 Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A. Mol Cancer Ther. 2009 Jun;8(6):1714-23.
 Download Picture         KEGG Link